405 related articles for article (PubMed ID: 16061860)
1. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
[TBL] [Abstract][Full Text] [Related]
2. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Amorós A; Tardón A; Carrato A; Serra C; Malats N; Real FX
J Clin Oncol; 2006 Aug; 24(22):3664-71. PubMed ID: 16877735
[TBL] [Abstract][Full Text] [Related]
4. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
5. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK
Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601
[TBL] [Abstract][Full Text] [Related]
6. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
López-Knowles E; Hernández S; Malats N; Kogevinas M; Lloreta J; Carrato A; Tardón A; Serra C; Real FX
Cancer Res; 2006 Aug; 66(15):7401-4. PubMed ID: 16885334
[TBL] [Abstract][Full Text] [Related]
8. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
9. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
Bakkar AA; Wallerand H; Radvanyi F; Lahaye JB; Pissard S; Lecerf L; Kouyoumdjian JC; Abbou CC; Pairon JC; Jaurand MC; Thiery JP; Chopin DK; de Medina SG
Cancer Res; 2003 Dec; 63(23):8108-12. PubMed ID: 14678961
[TBL] [Abstract][Full Text] [Related]
10. [Mutation of the FGFR3 oncogene is an independent and favorable prognostic factor for tumor-specific survival in patients with urothelial carcinoma of the upper urinary tract].
Burger M; Catto J; van Oers J; Zwarthoff E; Hamdy FC; Meuth M; Azzouri AR; Cussenot O; Wild PJ; Stoehr R; Hartmann A
Verh Dtsch Ges Pathol; 2006; 90():244-52. PubMed ID: 17867603
[TBL] [Abstract][Full Text] [Related]
11. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
12. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
13. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
[TBL] [Abstract][Full Text] [Related]
14. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
15. Progression in transitional cell carcinoma of the urinary bladder--analysis of Tp53 gene mutations by temperature gradients and sequence in tumor tissues and in cellular urine sediments.
Schlechte HH; Sachs MD; Lenk SV; Brenner S; Rudolph BD; Loening SA
Cancer Detect Prev; 2000; 24(1):24-32. PubMed ID: 10757120
[TBL] [Abstract][Full Text] [Related]
16. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.
Dahse R; Utting M; Werner W; Schimmel B; Claussen U; Junker K
Int J Oncol; 2002 Jan; 20(1):107-15. PubMed ID: 11743649
[TBL] [Abstract][Full Text] [Related]
17. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
[TBL] [Abstract][Full Text] [Related]
18. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
[TBL] [Abstract][Full Text] [Related]
19. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
20. Mutations of fibroblast growth factor receptor 3 gene (FGFR3) in transitional cell carcinoma of urinary bladder in Thai patients [Revision-2a].
Jantip J; Tanthanuch M; Kanngurn S; Karnchanawanichkul W; Pripatnanont C; Sangkhathat S; Thongsuksai P
J Med Assoc Thai; 2013 Aug; 96(8):976-83. PubMed ID: 23991606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
